China NT Pharma Group Co. Ltd. has provided an update regarding its agreement to acquire 100% of the issued shares in certain target companies. According to a supplemental agreement signed on 18 December 2025, the payment terms for the consideration shares have been amended. The company will now allot all consideration shares to the sellers on a pro rata basis within 30 days after the successful registration and receipt of a medical device registration certificate for the Portable Digital X-Ray Diagnostic Robot System from the Zhejiang Province Food and Drugs Administration, and after the transaction's closing. Additionally, the long stop date for completion of the transaction has been extended to 28 April 2026, unless otherwise agreed by the parties in writing. Other terms of the agreement remain unchanged.